A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors
The combination of AZD8186 and docetaxel was generally well tolerated, with the exception of neutropenia, which was effectively managed with the use of growth factor. Limited clinical activity was observed.
Authors
- Alexia Iasonos (ORCID: https://orcid.org/0000-0003-0471-8477)
- Anna Chen (ORCID: https://orcid.org/0000-0002-3090-3361)
- Mihail Gavriliuc (ORCID: https://orcid.org/0000-0002-5789-2842)
- Samsinah Hussain
- Jeffrey L. Silber (ORCID: https://orcid.org/0009-0008-9834-2071)
- Qin Zhou (ORCID: https://orcid.org/0000-0003-1225-2902)
- Naoko Takebe (ORCID: https://orcid.org/0000-0002-5790-4954)
- Alison M. Schram (ORCID: https://orcid.org/0000-0002-6070-2413)
- Lillian M. Smyth (ORCID: https://orcid.org/0000-0002-0986-9285)
- M.E. Reynolds (ORCID: https://orcid.org/0000-0002-8337-255X)
- D. H. Garrison
- Ecaterina E Ileana Dumbrava (ORCID: https://orcid.org/0000-0002-1959-0536)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Eli Lilly (United States) (US)
- Cornell University (US)
- National Cancer Institute (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105569
- Citations
- 2
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.61